OBJECTIVE: Leptin, the ob gene product, is an anorexigenic peptide secreted from adipose tissue. However, the mechanism of leptin clearanceadegradation has not been well determined in humans. The present study was undertaken to examine a possible involvement of liver in determining circulating leptin concentrations in humans. SUBJECTS: In the present study 58 healthy control subjects and 68 patients with liver cirrhosis (LC) without any renal dysfunction were randomly included. METHOD: The serum immunoreactive leptin (IRL) concentrations relative to the body mass index (BMI) were determined. Serum IRL and estradiol (E 2 ) concentrations were assayed by radioimmunoassay (RIA). RESULTS: The correlations between the BMI and circulating IRL concentrations were all signi®cant in male healthy controls (M-C), male patients with LC (M-LC), female healthy controls (F-C) and female patients with LC (F-LC). Circulating IRL concentrations were signi®cantly higher than control in F-LC but not M-LC groups. The ratio of circulating IRL concentrations to the BMI was signi®cantly higher in the M-LC group than in the M-C group and also signi®cantly higher in the F-LC group than in the F-C group. The correlation between the IRLaBMI ratio and serum total bilirubin concentrations was signi®cant (r 0.417, P`0.05) in the M-LC group, but not in the F-LC group. There was no signi®cant correlation of the IRLaBMI ratio to serum E 2 or albumin concentrations in either M-LC or F-LC groups.
Introduction
Leptin, the ob gene product, is found in genetically obese (obaob) mice. 1 Leptin is an anorexigenic peptide, which is secreted from adipose tissues and involved in the regulation of feeding behaviour in rodents. 2, 3 Serum leptin concentrations are well correlated with both body mass index (BMI) and total body fat mass in humans. 4, 5 Various humoral factors have been reported to affect circulating leptin concentrations in vivo. 6 ± 10 In addition, recent observations indicate the possible involvement of leptin in glucose metabolism, by modulating pancreatic b-cell insulin secretion 11 ± 14 and peripheral insulin sensitivities. 15 ± 17 However, the mechanism of leptin clearancea degradation has not been well established in humans. Since the highest level of radioactive leptin at all time points were found in the serum, liver, and kidney of mice, 18 kidney and liver are proposed to be the most likely organs which degrade circulating leptin in vivo. It was demonstrated that endogenous leptin is cleared from the circulation in the kidney by glomerular ®ltration, followed by metabolic degradation in the renal tubules of Zucker (faafa) 19 and Sprague ± Dawley rats. 20, 21 In humans, circulating leptin concentrations are related to the degree of renal function, assessed by 1aplasma creatinine. 22 In contrast, it has been recently reported that intact leptin is increased in patients with end-stage renal disease, although increased production may account for the high concentrations of leptin. 23 Serum leptin concentrations are markedly elevated in the patients with chronic renal failure and higher plasma insulin, than in those with lower plasma insulin concentrations. 24 Recently, Meyer et al 25 calculated that renal leptin uptake could account for approximately 80% of all leptin removal from plasma in humans. In patients with intact renal function, there is a net renal uptake of 12% of circulating leptin, whereas in patients with renal insuf®ciency there is no renal uptake of leptin. 26 The issue of whether a kidney can degrade all leptin secreted from adipose tissues, or the possibility that leptin may be degraded in liver, have not been examined in humans. The present study was undertaken to examine a possible involvement of liver metabolism in determining circulating leptin concentrations by *Correspondence: Dr Hiroyuki Shimizu, First Department of Internal Medicine, Gunma University School of Medicine, 3-39-22 Showa-machi, Maebashi Gunma 371-8511, Japan. Abbreviations: BMI ± body mass index, IRL ± immunoreactive leptin, LC ± liver cirrhosis, M-C ± male control, F-C ± female control, M-LC ± male with liver cirrhosis, F-LC ± female with liver cirrhosis.
comparing the circulating leptin concentration relative to the BMI in healthy control subjects and patients with liver cirrhosis (LC).
Subjects and methods

Subjects
Normal healthy control subjects (29 men (M-C) and 29 women (F-C)) and patients with LC (29 men (M-LC) and 39 women (F-LC)) were randomly selected and included in this study. Details of all subjects are shown in Table 1 ± no subjects had renal dysfunction. The diagnosis of LC was based on the laboratory ®ndings including serum concentrations of glutamic oxaloacetic transaminase (L-Type Wako GOT: Wako Junyaku Industries, Co., Osaka, Japan) and glutamic pyruvic transaminase (L-Type Wako GPT, Wako Junyaku Industries) radiological ®ndings by abdominal echography and computed tomography (CT), andaor histological observations of biopsied liver tissue specimen. The pathogenesis of LC was hepatitis B virus infection (three patients; 4.4%), hepatitis C virus infection (55 patients; 80.9%), alcoholic liver damage (three patients; 4.4%), primary biliary cirrhosis (three patients; 4.4%) and unknown viral infection (four patients; 5.9%). The subjects included in this study were not fasting, and had eaten a breakfast meal. All blood samples were obtained from a cubital vein in the morning.
Assays
The serum immunoreactive leptin (IRL) concentration was measured by commercially available radioimmunoassay (RIA) kit (Linco Research, Inc., St Charles, MO). 27 Within-and between-assay variations were 3.4 ± 8.3% and 3.0 ± 6.2%. The serum albumin concentration was measured by automatic analyzer using a diagnostic kit (Iatro®ne ALB: Diatron, Inc., Tokyo, Japan) according to the brom-cresol-green (BCG) method. Serum total bilirubin level was measured by automatic analyzer using a diagnostic kit (T-Bil-C: Kokusai Shiyaku, Tokyo, Japan) according to the enzymatic method. Circulating estradiol (E 2 ) level was assayed by automatic analyzer using a diagnostic kit (AIA-PACK E 2 : Tosoh Co., Tokyo, Japan) according to the enzyme immunoassay method.
Statistical analysis
All data were expressed as mean AE s.e.m. The statistical analysis of the difference was performed by the analysis of variance (ANOVA), followed by Student's t-test and Duncan's multiple range test for the individual comparisons of the means. Regression analysis was used to compare the ratio of circulating IRL levels to the BMI with serum albumin, total bilirubin, and E 2 concentrations in each group.
Results
There was no difference in the BMI between normal healthy control and LC groups for both genders ( Table  1 ). The correlations between the BMI and circulating IRL concentrations were signi®cant in M-C (r 0.509, P`0.01), M-LC (r 0.706, P`0.001), F-C (r 0.541, P`0.01) and F-LC (r 0.817, P`0.001) groups (Figure 1 ). The slopes were steeper in LC groups of both genders. Circulating IRL levels tended to be higher in the M-LC than in the M-C group, but the difference between the M-C and M-LC groups was not signi®cant (Figure 2 ). Circulating IRL levels were signi®cantly higher in the F-LC than in the F-C group (Figure 3) . Furthermore, the rate of increase in serum IRL concentrations with the BMI was assessed by the ratio of serum IRL concentrrations to the BMI (IRLaBMI). The IRLaBMI ratio was signi®cantly higher in the M-LC than the M-C group and also, in the F-LC than in the F-C group. This result indicates that circulating IRL concentrations are higher in L-C patients, relative to their BMI, an index of body fat mass.
The average of serum albumin and total bilirubin concentrations in the patients with LC was 3.67AE 0.05 gadl and 1.29AE 0.06 mgadl, respectively, and gender differences were not observed in serum albumin, total bilirubin and E 2 concentrations as shown in Table 2 . To evaluate the correlation of the IRLaBMI ratio to liver function in each gender, the correlation of the IRLaBMI ratio to circulating albumin, total bilirubin and E 2 concentrations were calculated in the LC groups (Table 2 ). There was no difference in serum total bilirubin concentrations between both genders with LC (M-LC: 1.23AE 0.09 mgaml, F-LC: 1.33 AE 0.08 mgaml). The correlation between the IRLaBMI ratio and serum total bilirubin concentrations (r 0.417, P`0.05) was statistically signi®cant in the M-LC group, but not in the F-LC group. There was no difference in serum albumin concentrations between both genders with LC (M-LC: 3.75AE 0.07 gadl, F-LC: 3.61AE 0.10 gadl). There was no signi®cant correlation of the IRLaBMI ratio to serum albumin concentrations in both the M-LC and F-LC groups. In addition, there was no difference in serum E 2 concentrations between both genders with LC (M-LC: 66.24AE 4.23 pgaml, F-LC: 59.38AE 6.49 pgaml). No signi®cant correlation of the IRLaBMI ratio to circulating E 2 concentrations was observed in both the M-LC and F-LC groups. M-C male control subjects; M-LC male patients with liver cirrhosis (LC); F-C female control subjects; F-LC female patients with LC; BMI body mass index.
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Discussion
The degradation of leptin, released from adipose tissues, has not been fully explored in vivo. The present data clinically indicated that the existence of liver dysfunction, due to LC, increases the relative concentration of circulating IRL to the BMI in humans. The results obtained herein indicated that we have to take into consideration that circulating IRL concentrations are high, relative to their BMI, in LC patients when circulating IRL concentrations are evaluated. Reverse transcription-polymerase chain reaction studies demonstrated leptin receptor mRNA expression in the liver of mouse, rat and human hepatoma cell line. 28, 29 While it is possible that the existence of 
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LC is affecting the release of leptin from adipose tissue, the signi®cant positive correlation between the IRLaBMI ratio and total bilirubin concentrations, may indicate that the increased IRL concentrations are due to decreased removal of leptin from the circulation by the liver. However, the signi®cant, positive correlation of the IRLaBMI ratio to total bilirubin concentrations was observed only in the M-LC group. Gender differences in circulating IRL concentrations have been reported, 30, 31 with higher estrogen levels being associated with higher adipose tissue leptin production. 31 Since it is well known that estrogen is degraded in liver, 32 an increase in circulating leptin can be attributable to the increase of circulating estrogen concentrations in LC patients. But, estrogen does not appear to be a main factor which increases circulating IRL concentrations in patients with LC, because no signi®cant correlation of the IRLaBMI ratio to circulating E 2 concentrations was observed in either gender ( Table 2 ). The difference of sex hormone may affect the obtained results in the correlation of the IRLaBMI ratio to total bilirubin concentrations in female LC patients. However, there is a possibility that the difference of serum estrogen levels cannot completely explain the gender difference of circulating leptin concentrations in humans. 33 The observation that gender difference exists in the correlation of the IRLaBMI ratio to total bilirubin concentrations, may be attributable to changes in other sex hormones such as testosterone andaor other unknown genetic background differences between both genders.
Glucose intolerance is sometimes observed in LC patients. 34 Leptin can oppose the action of insulin by reducing phosphorylation of Insulin Receptor Substrate-1 (IRS-1) and enhancing the stimulation of the phosphoenolpyruvate carboxykinase mRNA concentration in human hepatoma (HepG2) cells. 15 Intravenous infusion of leptin into mice decreased the hepatic glycogen content. 35 Leptin also inhibits insulin binding in isolated rat adipocytes, 17 and attenuates insulin action on glucose storage in skeletal muscle. 36 In contrast, some investigators demonstrated that an acute increase in plasma leptin enhances insulin's ability to inhibit hepatic glucose production. 37 Leptin stimulates glucose transport and glycogen synthesis, and activates phosphatidyl inositol-3 kinase in C2C12 myotubes. 16, 33 Others have reported that leptin had no effect on both basal and insulinstimulated glucose transport in cultured rat and human skeletal muscle cells. 39 Taking these data into consideration, an interrelation between leptin and insulin action is still not conclusive. There remains a possibility that elevation of circulating leptin concentrations in LC patients may work to oppose peripheral insulin action in vivo, resulting in glucose intolerance.
In addition, leptin stimulates mitogen-activated protein kinase-dependent proliferation of mouse embryonic cell line, C3H10T1a2 cells. 40 Leptin receptor mRNA was detected in the liver of rodents 22, 23 and the addition of leptin, increases hepatic cell proliferation. 41 It is possible that an increase in circulating leptin concentrations may partially work as the proliferation factor of hepatocellular carcinoma cells in LC patients. An increase in circulating leptin may accelerate hepatic tumor growth rate in LC patients. However, further studies are necessary to determine these possibilities in vivo.
The present data demonstrated the rate of increase of circulating IRL concentrations with the BMI in LC patients. Thus, the liver may play a role in determining circulating leptin concentrations. 
